A Phase 2 Study of INCB018424, An Oral, Selective JAK1/JAK2 Inhibitor, in Patients with Advanced Polycythemia Vera (PV) and Essential Thrombocythemia (ET) Refractory to Hydroxyurea.

Srdan Verstovsek,Francesco Passamonti,Alessandro Rambaldi,Giovanni Barosi,Peter Rosen,Richard Levy,Edward C Bradley,Lee Schacter,William M Garrett,Kris Vaddi,Nancy Contel,Elisa Rumi,Elisabetta Gattoni,Mario Cazzola,Hagop Kantarjian,Tiziano Barbui,Alessandro Vannucchi

doi:10.1182/blood.v114.22.311.311

A Phase 2 Study of INCB018424, An Oral, Selective JAK1/JAK2 Inhibitor, in Patients with Advanced Polycythemia Vera (PV) and Essential Thrombocythemia (ET) Refractory to Hydroxyurea.

Srdan Verstovsek, Francesco Passamonti + Show 15 more

https://doi.org/10.1182/blood.v114.22.311.311

Copy DOI

Export

Save

Cite

Journal: Blood	Publication Date: Nov 20, 2009
Citations: 33

Affiliation: Istituti di Ricovero e Cura a Carattere Scientifico, University of Pavia, University of Bergamo, Policlinico San Matteo Fondazione, Tower Cancer Research Foundation, Incyte (United States), The University of Texas MD Anderson Cancer Center, University of Florence

#Essential Thrombocythemia Patients #Polycythemia Vera Patients #Essential Thrombocythemia #Dose Modification #Polycythemia Vera #Platelet Count #Advisory Committees #Incyte Corporation #Entity's Board #Speakers Bureau

Abstract
Full-Text
Similar Papers

Abstract

Listen

A Phase 2 Study of INCB018424, An Oral, Selective JAK1/JAK2 Inhibitor, in Patients with Advanced Polycythemia Vera (PV) and Essential Thrombocythemia (ET) Refractory to Hydroxyurea.

Full Text

Published Version

Check institute access

Open DOI Link

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Similar Papers

Paper Title

Journal

Date

Author

View more papers

More From: Blood

Paper Title

Journal

Date

Author

View more papers

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.

R Discovery Prime

A Phase 2 Study of INCB018424, An Oral, Selective JAK1/JAK2 Inhibitor, in Patients with Advanced Polycythemia Vera (PV) and Essential Thrombocythemia (ET) Refractory to Hydroxyurea.